|
2015 Dietary Guidelines Management Team
|
Other
|
ACF, CDC, FDA, HRSA, IHS, OS
|
NIDDK, NCI, OD/DPCPSI/ODP
|
The Dietary Guidelines Management Team includes federal staff representing the Departments of Health and Human Services and Agriculture throughout the Dietary Guidelines for Americans revision process and supports the Dietary Guidelines Advisory Committee from the planning phase to the final report phase.
|
|
5th Annual NICHD Infant Mortality Awareness 5-Kilometer Run/Walk/Roll
|
Meeting/ Workshop
|
OS
|
NICHD, NIMHD
|
The Institute welcomed all HHS staff and their families to the 5th Annual Infant Mortality Awareness 5K Run/Walk/Roll.
Infant mortality is one of the most important indicators of the health of a nation. According to a National Center for Health Statistics data brief issued in 2013, the United States ranked 27th in the world in infant mortality. Medical research, public health outreach, and social services have helped the overall U.S. infant mortality rate to decline during the 20th century. In spite of this general decline, infant mortality rates for certain populations, including African American, Puerto Rican, and American Indian/Alaskan Native infants remain above the U.S. average of 6.05 per 1,000 live births.
This event reaffirms the NIH commitment to conducting and supporting research and outreach that reduces the U.S. infant mortality rate, and the disparate rates that impact communities of color. It also aims to raise awareness about infant mortality, particularly in those communities where the rates are above the U.S. average, by highlighting ongoing efforts from the NICHD and other Institutes, Centers, and Offices to address this public health concern.
|
|
8th Annual Conference on the Science of Dissemination and Implementation
|
Meeting/ Workshop
|
AHRQ
|
NHLBI, NCCIH, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR
|
A forum for discussing the science of dissemination and implementation, the 7th annual conference aimed to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine.
|
|
A Pilot Study of Urinary Carcinogen Biomarkers in the Golestan Cohort Study
|
Research Initiative
|
CDC, FDA
|
NCI
|
We are performing a pilot study in the Golestan Cohort to compare exposure to different types of carcinogens (nicotine metabolites, polycyclic aromatic hydrocarbons [PAHs], tobacco-specific nitrosamines [TSNAs], and volatile organic compounds [VOCs]) and creatine in the urine of self-reported cigarette, chewing nass, water pipe, and opium users, and never users of these products. We also will examine the stability of these markers over time by taking advantage of repeated samples that were collected from a subset of participants. Results from the pilot study will then be used to evaluate the potential of future studies and evaluate their design.
|
|
A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews
|
Research Initiative
|
CDC
|
NCI
|
A cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure.
|
|
A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
CC
|
Dr. Marion Danis is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management.
|
|
A5295 Evaluation of Xpert Mycobacterium tuberculosis/rifampin (MTB/RIF) Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis (TB) Suspects
|
Research Initiative
|
CDC
|
NIAID
|
This initiative will estimate the sensitivity of a single Xpert Mycobacterium tuberculosis/rifampin (MTB/RIF) assay (performed on sputum) in TB suspects with at least one acid fast bacilli (AFB) sputum smear positive result and at least one culture result positive for Mycobacterium tuberculosis.
|
|
A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial
|
Research Initiative
|
CDC
|
NIAID
|
NIAID''s AIDS Clinical Trial Group (ACTG) network and CDC''s Tuberculosis Trials Consortium (TBTC) network are collaborating to enroll participants for this study (approximately half in each network). The completed trial will determine if the two proposed regimens can shorten tuberculosis treatment duration.
.
|
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT)
|
Research Initiative
|
FDA
|
NIDA
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health.
|
|
Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus
|
Research Initiative
|
FDA
|
NIAMS, NIAID
|
The National Institutes of Health (NIH), pharmaceutical companies and nonprofit organizations have together created the Accelerating Medicines Partnership (AMP) to develop new models for identifying and validating promising biological targets for new diagnostics and drug development. A major goal is to generate pre-competitive, disease-specific data that will be publicly accessible to the broad biomedical community for further research (http://www.nih.gov/science/amp/).
The partners have designed a project plan to address relevant challenges for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (AMP RA/SLE Program). The goal is to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs (synovium for RA, kidney and skin for lupus) and blood cells. The initial focus of research will be on RA and lupus, with the flexibility to expand in the future to related autoimmune diseases contingent on scientific feasibility and availability of resources.
|